Nebenwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 20–21
HOS-086604 · Präparat HOS-083306
20 Skin and subcutaneous tissue Common Sweating increased disorders Renal and urinary disorders Common Urine discoloration General disorders and Common Chest pain administration site conditions Influenza like illness Hepatobiliary disorders Uncommon Hepatocellular injury, in rare cases with fatal outcome* (see section 4.4) Investigations Common Increase of alanine aminotransferase (ALT) * Adverse reactions for which no frequency could be derived from clinical studies (i.e. where a specific adverse reaction was not observed in clinical trials but was reported post-marketing only) are indicated by an asterisk (*), and the frequency category has been calculated according to EU Guideline.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 06dcda53993eb81d2641a5f79e1b1bc267fc1a58ca4daab2534aa49ca989351b · Zeichen 3762–4796 im Abschnitt